Vaccination for hepatitis C virus: Closing in on an evasive target

Expert Review of Vaccines

Volumn 10, Issue 5, 2011, Pages 659-672

  Halliday, John ^a   Klenerman, Paul ^b   Barnes, Eleanor ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

hepatitis C virus; immunity; prophylactic vaccine; T cells; therapeutic vaccine

Indexed keywords

ADENOVIRUS VECTOR; BOCEPREVIR; CHONVAC C; CHRONVAC C; CICGB 230; CORE PROTEIN; DENDRITIC CELL VACCINE; DNA VACCINE; GI 5005; GLYCOPROTEIN E1; GLYCOPROTEIN E2; HEPATITIS C VACCINE; IC 41; INTERFERON; LAMBDA3 INTERFERON; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON; PEPTIDE VACCINE; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; RIBAVIRIN; TELAPREVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIROSOME VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS FUSION PROTEIN; VIRUS VECTOR;

ANTIGEN RECOGNITION; ANTIVIRAL THERAPY; BIOLISTIC TRANSFORMATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ELECTROPORATION; GENOTYPE; GOLD STANDARD; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VACCINATION; VIRUS CELL INTERACTION; VIRUS LOAD;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HEPACIVIRUS; HEPATITIS C; HUMANS; VACCINATION; VIRAL VACCINES;

EID: 79957622306     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.55     Document Type: Review

References (110)

1. WHO. Hepatitis C: global prevalence. Wkly Epidemiol. Rec. 72(46), 341-344 (1997).
2. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J. Hepatol. 51(2), 237-267 (2009).
3. Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 345(1), 41-52 (2001). (Pubitemid 32634271)
4. Afdhal NH. The natural history of hepatitis C. Semin. Liver Dis. 24(Suppl. 2), 3-8 (2004). (Pubitemid 39180700)
5. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusionassociated hepatitis C. N. Engl. J. Med. 332(22), 1463-1466 (1995).
6. Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol. 13(17), 2436-2441 (2007). (Pubitemid 46929498)
7. Pybus OG, Barnes E, Taggart R et al. Genetic history of hepatitis C virus in East Asia. J. Virol. 83(2), 1071-1082 (2009).
8. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42(4), 962-973 (2005). (Pubitemid 41401136)
9. Simmonds P. Viral heterogeneity of the hepatitis C virus. J. Hepatol. 31(Suppl. 1), 54-60 (1999). (Pubitemid 30002692)
10. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55(9), 1350-1359 (2006). (Pubitemid 44277369)
11. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat. Rev. Microbiol. 5(6), 453-463 (2007). (Pubitemid 46780082)
12. Reed KE, Rice CM. Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. Curr. Top. Microbiol. Immunol. 242, 55-84 (2000). (Pubitemid 29467521)
13. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J. Virol. 67(3), 1385-1395 (1993). (Pubitemid 23067645)
14. Flint M, Quinn ER, Levy S. In search of hepatitis C virus receptor(s). Clin. Liver Dis. 5(4), 873-893 (2001).
15. Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15(1), 41-63 (1995).
16. Grieve R, Roberts J, Wright M et al. Cost effectiveness of interferon a or peginterferon a with ribavirin for histologically mild chronic hepatitis C. Gut 55(9), 1332-1338 (2006). (Pubitemid 44277366)
17. Kwo PY, Lawitz EJ, McCone J et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon a-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre Phase 2 trial. Lancet 376(9742), 705-716 (2010).
18. Marcellin P, Forns X, Goeser T et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon a-2a or 2b to patients with chronic hepatitis C. Gastroenterology 140(2), 459-468 (2011).
19. Wiegand J, Buggisch P, Boecher W et al. Early monotherapy with pegylated interferon a-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 43(2), 250-256 (2006).
20. Farci P, Alter HJ, Govindarajan S et al. Lack of protective immunity against reinfection with hepatitis C virus. Science 258(5079), 135-140 (1992).
21. Prince AM, Brotman B, Huima T, Pascual D, Jaffery M, Inchauspe G. Immunity in hepatitis C infection. J. Infect Dis. 165(3), 438-443 (1992).
22. Osburn WO, Fisher BE, Dowd KA et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 138(1), 315-324 (2010).
23. Bassett SE, Guerra B, Brasky K et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology 33(6), 1479-1487 (2001). (Pubitemid 32496985)
24. Nascimbeni M, Mizukoshi E, Bosmann M et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J. Virol. 77(8), 4781-4793 (2003). (Pubitemid 36402828)
25. Mehta SH, Cox A, Hoover DR et al. Protection against persistence of hepatitis C. Lancet 359(9316), 1478-1483 (2002). (Pubitemid 34457766)
26. Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 37(3), 577-589 (2003). (Pubitemid 36258780)
27. Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 302(5645), 659-662 (2003). (Pubitemid 37310924)
28. Diepolder HM, Zachoval R, Hoffmann RM et al. Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346(8981), 1006-1007 (1995).
29. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med. 194(10), 1395-1406 (2001). (Pubitemid 33081515)
30. Schulze zur Wiesch J, Lauer GM, Day CL et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J. Immunol. 175(6), 3603-3613 (2005). (Pubitemid 41292019)
31. McKiernan SM, Hagan R, Curry M et al. Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40(1), 108-114 (2004). (Pubitemid 38877575)
32. Neumann-Haefelin C, Thimme R. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection. Genes Immun. 8(3), 181-192 (2007). (Pubitemid 46672051)
33. Shoukry NH, Grakoui A, Houghton M et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med. 197(12), 1645-1655 (2003). (Pubitemid 36745340)
34. Lauer GM, Barnes E, Lucas M et al. High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. Gastroenterology 127(3), 924-936 (2004). (Pubitemid 39208424)
35. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436(7053), 946-952 (2005). (Pubitemid 41191670)
36. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006). (Pubitemid 43237609)
37. Gruener NH, Lechner F, Jung MC et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J. Virol. 75(12), 5550-5558 (2001). (Pubitemid 32488148)
38. Urbani S, Boni C, Missale G et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol. 76(24), 12423-12434 (2002). (Pubitemid 35386928)
39. Wedemeyer H, He XS, Nascimbeni M et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol. 169(6), 3447-3458 (2002). (Pubitemid 35013196)
40. Blackburn SD, Shin H, Haining WN et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10(1), 29-37 (2009).
41. Ward SM, Fox BC, Brown PJ et al. Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. J. Hepatol. 47(3), 316-324 (2007). (Pubitemid 47189607)
42. Poli F, Scalamogna M, Aniasi A et al. A retrospective evaluation of HLA-A, B and -DRB1 matching in liver transplantation. Transpl. Int. 11(Suppl. 1), S347-S349 (1998). (Pubitemid 128683576)
43. Schmilovitz-Weiss H, Levy M, Thompson N, Dusheiko G. Viral markers in the treatment of hepatitis B and C. Gut 34(Suppl. 2), S26-S35 (1993). (Pubitemid 23156076)
44. Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA 104(14), 6025-6030 (2007). (Pubitemid 47175652)
45. Bartosch B, Bukh J, Meunier JC et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl Acad. Sci. USA 100(24), 14199-14204 (2003). (Pubitemid 37499214)
46. von Hahn T, Yoon JC, Alter H et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132(2), 667-678 (2007). (Pubitemid 46274668)
47. Timpe JM, Stamataki Z, Jennings A et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 47(1), 17-24 (2008). (Pubitemid 351171037)
48. Zhang P, Zhong L, Struble EB et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl Acad. Sci. USA 106(18), 7537-7541 (2009).
49. Helle F, Goffard A, Morel V et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81(15), 8101-8111 (2007). (Pubitemid 47101496)
50. Kamal SM, Fehr J, Roesler B, Peters T, Rasenack JW. Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. Gastroenterology 123(4), 1070-1083 (2002).
51. Cramp ME, Rossol S, Chokshi S, Carucci P, Williams R, Naoumov NV. Hepatitis C virusspecific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology 118(2), 346-355 (2000). (Pubitemid 30067508)
52. Barnes E, Gelderblom HC, Humphreys I et al. Cellular immune responses during high-dose interferon-a induction therapy for hepatitis C virus infection. J. Infect Dis. 199(6), 819-828 (2009).
53. Burton JR Jr, Klarquist J, Im K et al. Prospective analysis of effector and regulatory CD4+ T cells in chronic HCV patients undergoing combination antiviral therapy. J. Hepatol. 49(3), 329-338 (2008).
54. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-a and ribavirin therapy. Nat. Genet. 41(10), 1100-1104 (2009).
55. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41(10), 1105-1109 (2009).
56. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265), 798-801 (2009).
57. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262), 399-401 (2009).
58. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons a and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131(6), 1887-1898 (2006). (Pubitemid 44958521)
59. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197(5), 633-642 (2003). (Pubitemid 36314658)
60. Heller T, Saito S, Auerbach J et al. An in vitro model of hepatitis C virion production. Proc. Natl Acad. Sci. USA 102(7), 2579-2583 (2005). (Pubitemid 40279419)
61. Mercer DF, Schiller DE, Elliott JF et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7(8), 927-933 (2001). (Pubitemid 32756430)
62. Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med. 12(2), 190-197 (2006). (Pubitemid 43214745)
63. Bettauer RH. Chimpanzees in hepatitis C virus research: 1998. J. Med. Primatol. 39(1), 9-23 (2010).
64. Maher L, White B, Hellard M et al. Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. Vaccine 28(45), 7273-7278 (2010).
65. Farci P, Shimoda A, Wong D et al. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl Acad. Sci. USA 93(26), 15394-15399 (1996). (Pubitemid 27009611)
66. Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 436(7053), 961-966 (2005). (Pubitemid 41191672)
67. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol. Rev. 239(1), 99-108 (2011).
68. Law M, Maruyama T, Lewis J et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med. 14(1), 25-27 (2008).
69. Sarobe P, Lasarte JJ, Zabaleta A et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J. Virol. 77(20), 10862-10871 (2003). (Pubitemid 37204279)
70. Large MK, Kittlesen DJ, Hahn YS. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J. Immunol. 162(2), 931-938 (1999). (Pubitemid 29035418)
71. Semmo N, Barnes E, Taylor C et al. T-cell responses and previous exposure to hepatitis C virus in indeterminate blood donors. Lancet 365(9456), 327-329 (2005). (Pubitemid 40139110)
72. Rollier C, Depla E, Drexhage JA et al. Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol. 78(1), 187-196 (2004). (Pubitemid 37549731)
73. Barnes E, Folgori A, Aston S. Phase I trial of a highly immunogenic T-cell vacine for HCV based on novel adenoviral vectors from rare serotypes. Hepatology 50, 4(Suppl.), 105A (2009).
74. Depraetere S, Van Kerschaever E, Van Vlierberghe H et al. Long term response to interferon treatment in chronic hepatitis C patients is associated with a significant reduction in anti-E1 envelope antibody titers. J. Med. Virol. 60(2), 126-132 (2000). (Pubitemid 30036787)
75. Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA 91(4), 1294-1298 (1994). (Pubitemid 24058997)
76. Frey SE, Houghton M, Coates S et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28(38), 6367-6373 (2010).
77. Leroux-Roels G, Depla E, Hulstaert F et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine 22(23-24), 3080-3086 (2004). (Pubitemid 39037210)
78. Nevens F, Roskams T, Van Vlierberghe H et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 38(5), 1289-1296 (2003). (Pubitemid 37314839)
79. Wedemeyer H, Mazur W, Nevens F. Factors influencing progression of liver fibrosis in patients with chronic hepatitis C: results of the 3-year T2S-918-HCV study with HCVE1 therapeutic vaccine. J. Hepatol. 48, S27-S28 (2008).
80. Habersetzer F, Baumert TF, Stoll-Keller F. GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr. Opin. Mol. Ther. 11(4), 456-462 (2009).
81. Pockros P, Jacobson, Boyer T et al. GI-5005 therapeutic vaccine plus PEG-IFN/ribavirin improves sustained virological response versus PEG-IFN/ ribavirin in prior non-responders with genotype-1 chronic HCV infection. Hepatology 52(Suppl. 4), 107A (2010).
82. Drane D, Maraskovsky E, Gibson R et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX vaccine: a Phase I study in healthy volunteers. Hum. Vaccin. 5(3), 151-157 (2009).
83. Kaneko T, Moriyama T, Udaka K et al. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur. J. Immunol. 27(7), 1782-1787 (1997). (Pubitemid 27302864)
84. Klade CS, Wedemeyer H, Berg T et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134(5), 1385-1395 (2008).
85. Wedemeyer H, Schuller E, Schlaphoff V et al. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 27(37), 5142-5151 (2009).
86. Firbas C, Boehm T, Buerger V et al. Immunogenicity and safety of different injection routes and schedules of IC41, a hepatitis C virus (HCV) peptide vaccine. Vaccine 28(12), 2397-2407 (2010).
87. Klade CS, von Gabain A, Manns MP. Significant continuous viral load decline in treatment-naive HCV genotype 1 patients after therapeutic peptide vaccination with IC41. Programs and Abstracts of the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, October 30-November 1 2009 (Abstract 1558).
88. Rossignol JF. Thiazolides: a new class of antiviral drugs. Expert Opin. Drug Metab. Toxicol. 5(6), 667-674 (2009).
89. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB. Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin. Gastroenterology 136(3), 856-862 (2009).
90. Yutani S, Komatsu N, Shichijo S et al. Phase I clinical study of a peptide vaccination for hepatitis C virus-infected patients with different human leukocyte antigen-class I-A alleles. Cancer Sci. 100(10), 1935-1942 (2009).
91. Yutani S, Yamada A, Yoshida K et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine 25(42), 7429-7435 (2007). (Pubitemid 47484009)
92. Gowans EJ, Roberts S, Jones K et al. A Phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J. Hepatol. 53(4), 599-607 (2010).
93. Davis BS, Chang GJ, Cropp B et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol. 75(9), 4040-4047 (2001). (Pubitemid 32410116)
94. Boyer JD, Robinson TM, Kutzler MA et al. Protection against simian/human immunodeficiency virus (SHIV) 6P in macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc. Natl Acad. Sci. USA 104(47), 18648-18653 (2007). (Pubitemid 350210751)
95. Chong SY, Egan MA, Kutzler MA et al. Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(6P) challenge in rhesus macaques. Vaccine 25(26), 4967-4982 (2007). (Pubitemid 46843429)
96. Boyer JD, Robinson TM, Kutzler MA et al. SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques. J. Med. Primatol. 34(5-6), 262-270 (2005). (Pubitemid 41179588)
97. Sallberg M, Frelin L, Weiland O. DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. Expert Opin. Biol. Ther. 9(7), 805-815 (2009).
98. Wang B, Boyer J, Srikantan V et al. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates. DNA Cell Biol. 12(9), 799-805 (1993). (Pubitemid 24295356)
99. Davis HL, Whalen RG, Demeneix BA. Direct gene transfer into skeletal muscle in vivo: factors affecting efficiency of transfer and stability of expression. Hum. Gene Ther. 4(2) 151-159 (1993). (Pubitemid 23153207)
100. Yang NS, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc. Natl Acad. Sci. USA 87(24), 9568-9572 (1990). (Pubitemid 120016484)
101. Roy MJ, Wu MS, Barr LJ et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19(7-8), 764-778 (2000).
102. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 6(4), 508-514 (1999). (Pubitemid 29192659)
103. Gronevik E, Mathiesen I, Lomo T. Early events of electroporation-mediated intramuscular DNA vaccination potentiate Th1-directed immune responses. J. Gene Med. 7(9), 1246-1254 (2005). (Pubitemid 41335176)
104. Peng JL, Zhao YG, Mai JH et al. Non-cytolytic antigen clearance in DNA-vaccinated mice with electroporation. Acta Pharmacol. Sin. 28(7), 1024-1030 (2007).
105. Sallberg M, Frelin L, Diepolder H et al. A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. Presented at: 44th Annual Meeting of the European Association for the Study of the Liver. Copenhagen, Denmark, 23-26 April 2009.
106. Alvarez-Lajonchere L, Shoukry NH, Gra B et al. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J. Viral Hepat. 16(3), 156-167 (2009).
107. Habersetzer F, Zarski J-P, Leroy V et al. A novel vectorized HCV therapeutic vaccine (TG4040): results of a Phase I study in naive patients chronically infected by HCV. Presented at: 44th Annual Meeting of the European Association for the Study of the Liver. Copenhagen, Denmark, 23-26 April 2009.
108. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2(7), 395-403 (2002).
109. Hilleman MR. Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. Vaccine 19(15-16), 1837-1848 (2001). (Pubitemid 32178329)
110. Vollmer J. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR. Expert Opin. Biol. Ther. 5(5), 673-682 (2005). (Pubitemid 40780550)